移动健康应用于妊娠期高血压疾病患者血压管理的前瞻性验证:随机对照试验研究方案
这是一项前瞻性、随机、单中心试验,计划纳入580名符合妊娠期高血压疾病(HDP)标准或存在妊娠相关高血压高风险的孕妇,随机分为移动健康(mHealth)干预组或标准护理组。主要终点为入组至分娩后1个月收缩压的差异,次要终点包括多种血压参数、产科结局、体重指数轨迹、步数、情绪评估和药物依从性。研究旨在评估Heart4U应用对HDP患者血压管理的潜在作用。
要点
- 前瞻性随机单中心试验,计划纳入580名HDP或高风险孕妇。
- 主要终点为入组至分娩后1个月收缩压差异。
- 干预为mHealth应用(Heart4U),对照为标准护理。
核心结论
- 本研究强调mHealth干预(如Heart4U应用)在改善HDP孕妇血压管理方面的潜力。
- 通过利用技术增强参与、沟通和监测,本研究旨在对HDP相关的母体、胎儿和产后结局产生积极影响。
- 这种创新方法展示了个性化技术驱动解决方案在管理复杂健康状况方面的潜力。
研究设计与样本
- 前瞻性、随机、单中心试验,计划纳入580名符合HDP标准或存在妊娠相关高血压高风险的孕妇。
- 高风险因素包括多胎妊娠、肥胖、糖尿病或既往妊娠因HDP导致早产。
- 参与者随机分为mHealth干预组或标准护理组。
- 主要终点为入组至分娩后1个月收缩压的差异。
- 次要终点包括多种血压参数、产科结局、体重指数轨迹、步数、情绪评估和药物依从性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertensive disorders of pregnancy (HDP) pose significant risks to both maternal and fetal health, contributing to global morbidity and mortality. Management of HDP is complex, particularly because of concerns regarding potential negative effects on utero-placental circulation and limited therapeutic options due to fetal safety. Our study investigates whether blood pressure monitoring through a mobile health (mHealth) application can aid in addressing the challenges of blood pressure management in pregnant individuals with HDP. Additionally, we aim to assess whether this intervention can improve short-term maternal and fetal outcomes and potentially mitigate long-term cardiovascular consequences. METHODS: This prospective, randomized, single-center trial will include 580 pregnant participants who meet the HDP criteria or who have a heightened risk of pregnancy-related hypertension due to factors such as multiple pregnancies, obesity, diabetes, or a history of HDP in prior pregnancies leading to preterm birth. Participants will be randomized to either the mHealth intervention group or the standard care group. The primary endpoint is the difference in systolic blood pressure from enrollment to 1 month after childbirth. The secondary endpoints include various blood pressure parameters, obstetric outcomes, body mass index trajectory, step counts, mood assessment, and drug adherence. CONCLUSIONS: This study emphasizes the potential of mHealth interventions, such as the Heart4U application, to improve blood pressure management in pregnant individuals with HDP. By leveraging technology to enhance engagement, communication, and monitoring, this study aims to positively impact maternal, fetal, and postpartum outcomes associated with HDP. This innovative approach demonstrates the potential of personalized technology-driven solutions for managing complex health conditions. TRIAL REGISTRATION: ClinicalTrials.gov NCT05995106. Registered on 16 August 2023.
引用
- Kwun JS, Choi J, Yoon YE, et al. Prospective validation of a mobile health application for blood pressure management in patients with hypertensive disorders of pregnancy: study protocol for a randomized controlled trial. Trials. 2024. PMID: 38956675. doi:10.1186/s13063-024-08200-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。